Introduction {#tca12859-sec-0005}
============

Lung cancer is a leading cause of cancer‐related death worldwide. It is estimated that 154 000 patients will die from lung cancer in the United States in 2018.[1](#tca12859-bib-0001){ref-type="ref"} Lung cancer is also the leading cause of cancer‐related death in China, with approximately 610 000 deaths reported in 2015.[2](#tca12859-bib-0002){ref-type="ref"}, [3](#tca12859-bib-0003){ref-type="ref"} Non‐small‐cell lung cancer (NSCLC) constitutes over 80% of all new lung cancer diagnoses.[4](#tca12859-bib-0004){ref-type="ref"} As with most other cancer treatments, the therapy for NSCLC depends on tumor stage. Platinum‐based chemotherapy is the standard treatment for NSCLC, but the five‐year survival rate for advanced NSCLC is only 2%.[5](#tca12859-bib-0005){ref-type="ref"}

Tyrosine kinase inhibitors (TKIs) have shown profound clinical efficacy in NSCLC patients harboring *EGFR* mutations, and are now the preferred first‐line treatment for advanced NSCLC with *EGFR* mutations.[6](#tca12859-bib-0006){ref-type="ref"} Given the benefit of TKI therapy for *EGFR* mutations, international guidelines were updated in 2011 to recommend *EGFR* molecular testing for NSCLC patients to select candidates for TKI therapy.[5](#tca12859-bib-0005){ref-type="ref"}, [7](#tca12859-bib-0007){ref-type="ref"}, [8](#tca12859-bib-0008){ref-type="ref"}, [9](#tca12859-bib-0009){ref-type="ref"} *EGFR* mutations more frequently occur in women, non‐smokers, and NSCLC patients with adenocarcinomas, and vary between gender and different pathological tumor types.[10](#tca12859-bib-0010){ref-type="ref"} Furthermore, *EGFR* mutation rates are much higher in Asian than in Caucasian patients (approximately 50% vs. 10%).[5](#tca12859-bib-0005){ref-type="ref"}, [11](#tca12859-bib-0011){ref-type="ref"}

The benefits of TKI therapy in patients with *EGFR*‐mutant NSCLC are well recognized, but the real‐world practice of *EGFR* testing for NSCLC patients varies between countries. In 2010, the *EGFR* testing rate for NSCLC patients was 16.8% in the United States,[12](#tca12859-bib-0012){ref-type="ref"} compared to 63.5% in Korea.[13](#tca12859-bib-0013){ref-type="ref"} In 2012, a Swedish study reported that 49% of advanced NSCLC patients were tested for the *EGFR* gene,[11](#tca12859-bib-0011){ref-type="ref"} while a 2014 study conducted in New Zealand revealed the *EGFR* testing rate to be 67%.[14](#tca12859-bib-0014){ref-type="ref"} As *EGFR* mutations are more common in Asian compared to Western patients, *EGFR* molecular testing in Chinese patients is important. However, the *EGFR* testing rate in China was 9.6% in 2010,[15](#tca12859-bib-0015){ref-type="ref"} and although it increased to 18.3% in 2011, it was much lower than the testing rate in Japan in the same year at 64.8%.[16](#tca12859-bib-0016){ref-type="ref"}

As indicated, the *EGFR* testing rate is relatively low in China, and limited updated data are available on the real‐world practice of *EGFR* testing post‐2011, when several international and national guidelines were revised to recommend *EGFR* molecular testing for advanced NSCLC. Thus, this study investigated the real‐world practice of *EGFR* testing in North China, with secondary objectives of the clinical and social factors associated with *EGFR* testing rates, the positive rates yielded from different testing platforms, and clinical outcomes in patients with or without *EGFR* testing (NCT02620657).

Methods {#tca12859-sec-0006}
=======

Study design {#tca12859-sec-0007}
------------

This was a non‐interventional, observational study of *EGFR* gene testing status in advanced NSCLC patients in North China (NCT02620657). Treatment‐naïve patients or those with postoperative recurrent stage IIIB/IV NSCLC across 28 research centers in 11 cities in North China were included. These cities were divided into three tiers according to their level of economy, education, and industry. Beijing, the capital of China, is a Tier‐1 city; Tier‐2 cities included Harbin, Changchun, Shenyang, and Dalian, which are either provincial capital cities or bigger developed cities; Tier‐3 included six developing cities, Anshan, Daqing, Jilin, Jinzhou, Siping, and Yanji.

The study was conducted in accordance with the Declaration of Helsinki, and in line with the principles of Good Clinical Practice, as well as applicable regulatory requirements. The institutional review boards at each site approved the study protocol before patient enrollment. The requirement of informed consent was waived because of the observational nature of this study.

Patients and inclusion/exclusion criteria {#tca12859-sec-0008}
-----------------------------------------

The inclusion criteria were as follows: (i) patients with histologically or pathologically confirmed stage IIIB/IV NSCLC, (ii) treatment‐naïve patients or those with postoperative recurrent NSCLC between 1 January and 31 December 2014 in North China, and (iii) NSCLC patients with complete medical records.

Patients' medical records were reviewed by experienced physicians or trained nurses. Baseline clinical characteristics included: age at diagnosis, gender, smoking history, tumor histology, tumor node metastasis (TNM) stage (according to the 7th edition of the American Joint Committee on Cancer TNM staging system), *EGFR* test result, *EGFR* detection method, therapy regimen, and survival outcome. This study mainly assessed the *EGFR* testing rates in patients with adenocarcinoma, and the proportions of non‐adenocarcinoma patients in each center were kept below 10%.

Study objectives {#tca12859-sec-0009}
----------------

The primary objective of this study was the real‐world practice of *EGFR* gene testing in advanced NSCLC patients in North China. The secondary objectives included *EGFR* mutation status, platforms and sample types used for *EGFR* detection, potential factors affecting *EGFR* testing, and overall survival (OS) of patients who did or did not undergo *EGFR* testing and their first‐line treatment regimens.

Statistical analysis {#tca12859-sec-0010}
--------------------

The estimated *EGFR* gene testing rate was 30.04% in accordance with a previously published study.[17](#tca12859-bib-0017){ref-type="ref"} Overall, an enrollment target of 3000 individuals with NSCLC was set for this study using Wilson\'s estimate calculations. Analysis was based on a full analysis set for all patients. Categorical data were presented as frequencies and percentages; continuous variables were expressed as mean, standard deviation, median, minimum, and maximum. Logistic regression analysis was performed to identify factors associated with *EGFR* gene testing. Independent variables associated with *EGFR* testing based on bivariate chi‐square tests were then analyzed by multivariate logistic regression. The OS was defined from the date of NSCLC diagnosis to the date of death, 30 March 2017 (censored observation), disease progression after third‐line therapy, or the end of third‐line therapy, whichever came first. All statistical analyses were performed using SAS version 7.1 (SAS Institute Inc., Cary, NC, USA). All tests were two‐sided and statistical significance was defined as *P* \< 0.05.

Results {#tca12859-sec-0011}
=======

Patient characteristics {#tca12859-sec-0012}
-----------------------

A total of 26 187 NSCLC patients from 28 research centers in North China were screened; 2809 patients met the inclusion/exclusion criteria and were enrolled in the study. The patients' clinical characteristics are summarized in Table [1](#tca12859-tbl-0001){ref-type="table"}. The majority of patients were newly diagnosed with NSCLC (93.52%), stage IV (79.49%), with adenocarcinomas (90.78%). The proportions of women and non‐smokers (never and former) were 43.57% and 70.02%, respectively. More than 60% of patients had urban medical insurance, and 87.75% (2465/2809) of patients were treated in Tier‐1 and Tier‐2 cities in North China.

###### 

Clinical characteristics and *EGFR* mutation testing rates

  Characteristic                                             Patients, n (%)   *EGFR* testing rate (%)
  ---------------------------------------------------------- ----------------- -------------------------
  Total                                                      2809 (100)        1195/2809 (42.54)
  Age at diagnosis (years)                                                     
  \< 65                                                      2112 (75.19)      940/2112 (42.54)
  ≥ 65                                                       697 (24.81)       255/697 (36.59)
  Gender                                                                       
  Male                                                       1585 (56.43)      624/1585 (39.37)
  Female                                                     1224 (43.57)      571/1224 (46.65)
  Tumor stage                                                                  
  IIIB                                                       576 (20.51)       187/576 (32.47)
  IV                                                         2233 (79.49)      1008/2233 (45.14)
  Histology                                                                    
  Adenocarcinoma                                             2550 (90.78)      1146/2550 (44.94)
  Non‐squamous carcinoma                                     259 (9.22)        49/259 (18.92)
  Smoking                                                                      
  Never                                                      1605 (57.14)      729/1605 (45.42)
  Former                                                     362 (12.89)       185/362 (51.10)
  Current                                                    842 (29.98)       281/842 (33.37)
  Treatment history[†](#tca12859-note-0001){ref-type="fn"}                     
  Naïve                                                      2627 (93.52)      1129/2627 (42.98)
  Recurrence                                                 180 (6.41)        65/180 (36.11)
  Medical insurance[‡](#tca12859-note-0002){ref-type="fn"}                     
  Urban medical insurance                                    1877 (66.82)      837/1877 (44.59)
  Rural cooperative medical insurance                        707 (25.17)       258/707 (36.49)
  Self‐funded                                                224 (7.97)        99/224 (44.20)
  City level                                                                   
  Tier‐1 city                                                717 (25.53)       495/717 (69.04)
  Tier‐2 city                                                1748 (62.23)      652/1728 (37.30)
  Tier‐3 city                                                344 (12.25)       48/344 (13.95)
  Hospital level                                                               
  Grade‐1 level A General Hospital                           1491 (53.08)      585/1491 (39.24)
  Grade‐1 level A Specialized Hospital                       1211 (43.11)      580/1211 (47.89)
  Grade‐1 level B Specialized Hospital                       75 (2.67)         15/75 (20.00)
  Grade‐2 level A Specialized Hospital                       32 (1.14)         15/32 (46.88)

Data was missing for two patients.

Includes one patient with unknown medical insurance status who underwent *EGFR* testing.

*EGFR* mutation testing {#tca12859-sec-0013}
-----------------------

In this study, 42.54% (1195/2809) of NSCLC and 44.94% of adenocarcinoma patients underwent *EGFR* testing (Table [1](#tca12859-tbl-0001){ref-type="table"}). *EGFR* testing rates were higher in patients aged \< 65 years, women, patients with stage IV NSCLC, and non‐smokers. When stratified by city level, hospital level, and medical insurance type, testing rates ranged from 13.95% to 69.04% (patients treated in a Tier‐1 city).

The highest *EGFR* testing rate of 73.51% (111/151) was found in patients whose tumor samples were obtained by lymph node puncture (Fig [1](#tca12859-fig-0001){ref-type="fig"}), followed by those obtained by lung puncture.

![*EGFR* testing rates of study patients. ECOG, Eastern Cooperative Oncology Group.](TCA-9-1461-g012){#tca12859-fig-0001}

A total of 2498 (88.93%) patients were referred for *EGFR* gene testing by their physician. However, more than half (1317/2498, 52.72%) of the patients refused to undergo *EGFR* testing even when recommended by their doctors, and this accounted for 81.60% of all non‐tested patients (Fig [2](#tca12859-fig-0002){ref-type="fig"}a). Reasons that *EGFR* testing was not conducted included the high cost of testing (46.77%), expensive TKI therapy (37.66%), and time constraints as the patient required immediate therapy (Fig [2](#tca12859-fig-0002){ref-type="fig"}b).

![(**a**) Proportion of patients who did not undergo *EGFR* testing. (![](TCA-9-1461-g010.jpg "image")) No testing although physician recommended test, (![](TCA-9-1461-g015.jpg "image")) No testing because physician did not recommend test, (![](TCA-9-1461-g017.jpg "image")) other reasons, and (![](TCA-9-1461-g008.jpg "image")) unknown reasons. (**b**) Patient reasons for declining *EGFR* testing although a physician recommended the test. TKI, tyrosine kinase inhibitor. (![](TCA-9-1461-g013.jpg "image")) High detection fee, (![](TCA-9-1461-g004.jpg "image")) expensive TKI, (![](TCA-9-1461-g014.jpg "image")) unknown, and (![](TCA-9-1461-g005.jpg "image")) time constraint.](TCA-9-1461-g009){#tca12859-fig-0002}

Clinical and social features associated with *EGFR* testing {#tca12859-sec-0014}
-----------------------------------------------------------

Associations between clinical and social variables with *EGFR* testing were assessed by multivariate logistic regression analysis. As shown in Table [2](#tca12859-tbl-0002){ref-type="table"}, *EGFR* testing was associated not only with a patient\'s clinical characteristics, such as tumor pathology, tumor stage, and smoking status, but also with social features, including medical insurance type and city level, as well as willingness to follow their doctor\'s recommendation for *EGFR* testing.

###### 

Independent factors associated with *EGFR* testing[†](#tca12859-note-0003){ref-type="fn"}

  Factors                                         Odds ratio   95% CI           *P*
  ----------------------------------------------- ------------ ---------------- -----------
  Stage                                                                         
  IIIB                                            Reference    0.005            
  IV                                              0.715        0.566--0.902     
  Histological type                                                             
  Adenocarcinoma                                  Reference    \< 0.001         
  Non‐adenocarcinoma                              0.437        0.300--0.637     
  Smoking status                                                                
  Never                                           Reference    \< 0.001         
  Former                                          1.102        0.828--1.467     0.506
  Current                                         0.660        0.537--0.812     \< 0.001
  ECOG score                                                                    
  0                                               Reference                     \< 0.001
  1                                               1.079        0.810--1.437     0.603
  2                                               0.967        0.680--1.375     0.853
  ≥ 3                                             0.320        0.178--0.575     \< 0.001
  Procedure to obtain samples                                                   
  Lung puncture                                   Reference    \< 0.001         
  Lymph node puncture                             3.358        2.123--5.311     \< 0.0001
  Hydrothorax                                     0.979        0.727--1.317     0.887
  Endobronchial ultrasound                        0.612        0.338--1.106     0.104
  Bronchoscopy                                    0.578        0.457--0.732     \< 0.001
  Patient willingness to undergo *EGFR* testing                                 
  Testing without physician referral              Reference    \< 0.001         
  Testing with physician referral                 50.025       27.824--89.942   
  Medical insurance type                                                        
  Rural cooperative medical insurance             Reference    \< 0.001         
  Urban medical insurance                         1.556        1.255--1.928     \< 0.001
  Self‐funded                                     1.531        1.044--2.244     0.029
  City level                                                                    
  Tier‐1 city                                     Reference    \< 0.001         
  Tier‐2 city                                     0.127        0.097--0.167     \< 0.001
  Tier‐3 city                                     0.014        0.008--0.025     \< 0.001

Multivariate analyses were performed for variables of *P* \< 0.05 during univariate analysis by logistic regression model.

CI, confidence interval; ECOG, Eastern Cooperative Oncology Group.

*EGFR* testing was more likely to be performed in patients with adenocarcinoma, and with urban medical insurance, and less likely in smokers, those with Eastern Cooperative Oncology Group (ECOG) performance status ≥ 3, and in patients who were treated in Tier‐3 cities. A strong independent positive predictor for *EGFR* mutation testing was that the tumor sample was obtained by lymph node puncture (odds ratio \[OR\] 3.358, 95% confidence interval \[CI\] 2.123--5.311; *P* \< 0.0001).

*EGFR* mutation status {#tca12859-sec-0015}
----------------------

Among 1195 patients who underwent *EGFR* mutation testing, 555 had *EGFR* gene mutations. Most (493/555, 88.82%) of these were single mutations, including 480 patients with TKI‐sensitive‐*EGFR* mutations and 19 with resistant‐*EGFR* mutations.

Exon 19 deletions and exon 21 L858R mutations were the two most common sensitive‐*EGFR* mutations (Table [3](#tca12859-tbl-0003){ref-type="table"}). Exon 20 insertions were the most common TKI‐resistant *EGFR* mutations (9/13, 69.23%). Complex mutations harboring both TKI‐sensitive and TKI‐resistant *EGFR* mutations, such as T790M+L858R, T790M+L861Q, and G719X+S768I were found in 15 patients.

###### 

*EGFR* gene mutation status in *EGFR*‐mutant patients

  *EGFR* gene status           Patients (*n*), N = 555   Percentage (%)
  ---------------------------- ------------------------- ----------------
  Single mutation              493                       88.82
  *TKI‐sensitizing mutation*                             
  19Del                        235                       42.34
  L858R                        222                       40.00
  G719X                        15                        2.70
  L861Q                        5                         0.90
  S768I                        3                         0.54
  Total                        480                       86.49
  *TKI‐resistant mutation*                               
  Exon 20 insertion            9                         1.62
  T790M                        4                         0.72
  Total                        13                        2.34
  Complex mutation                                       
  T790M + L858R                2                         0.36
  T790M + L861Q                1                         0.18
  G719X + S768I                1                         0.18
  19Del + L858R                8                         1.44
  L858R + L861Q                1                         0.18
  G719X + L861Q                1                         0.18
  19Del + L858R + L861Q        1                         0.18
  Total                        15                        2.70
  Unknown mutation             47                        8.47

19Del, Exon 19 deletion; TKI, tyrosine kinase inhibitor.

Platforms used for *EGFR* mutation detection {#tca12859-sec-0016}
--------------------------------------------

Multiple molecular platforms are available to detect *EGFR* gene mutations. In this study, *EGFR* mutations were detected by real‐time PCR‐based methods, Sanger sequencing, and Luminex liquid chip, among others (Fig [3](#tca12859-fig-0003){ref-type="fig"}a). The most common was the PCR‐based method (861/1195, 72.05%).

![Different (**a**) platforms (![](TCA-9-1461-g011.jpg "image")) PCR‐based method, (![](TCA-9-1461-g019.jpg "image")) sanger sequencing, (![](TCA-9-1461-g001.jpg "image")) luminex liquid chip, and (![](TCA-9-1461-g018.jpg "image")) others and (**b**) specimens used for *EGFR* detection (%). (![](TCA-9-1461-g006.jpg "image")) Biopsy tumor sample, (![](TCA-9-1461-g016.jpg "image")) cytological sample, (![](TCA-9-1461-g003.jpg "image")) surgically resected sample, (![](TCA-9-1461-g002.jpg "image")) blood sample, and (![](TCA-9-1461-g007.jpg "image")) others.](TCA-9-1461-g020){#tca12859-fig-0003}

The *EGFR*‐positive rate from PCR‐based platforms was 45.99% (396/861), and 44.80% (56/125) for Sanger sequencing and Luminex liquid chip methods. Thus, different *EGFR* detection methods yielded similar *EGFR*‐positive rates.

Specimens used for *EGFR* mutation detection {#tca12859-sec-0017}
--------------------------------------------

Tumor specimens used to detect *EGFR* gene mutations in this study were mainly biopsy tumor samples (807/1195, 67.53%), followed by cytological samples and surgically resected specimens. Less than 10% of patients had their blood samples tested for *EGFR* mutations (Fig [3](#tca12859-fig-0003){ref-type="fig"}b).

Considering the different types of tumor specimens used to detect the *EGFR* gene, the positive rates in biopsy tumor tissues, cytology specimens, and resected tumor specimens were 48.82%, 45.65%, and 51.97%, respectively. These specimens had similar positive rates for *EGFR* detection, and were higher than those gained from blood samples (20.59%).

First‐line treatment for patients with and without *EGFR* testing, and survival outcomes {#tca12859-sec-0018}
----------------------------------------------------------------------------------------

Consistent with current guidelines, in this survey the preferred first‐line treatment for patients with *EGFR* mutations (312/555, 56.22%) was TKI therapy, followed by chemotherapy for those without *EGFR* mutations (522/615, 84.88%). However, 5.85% (36/615) of patients without *EGFR* mutations and 5.27% (85/1614) of untested patients received TKI therapy.

In addition, the survival details of 1261 patients were further analyzed. The median OS in these patients was 22.67 months (range: 20.47--25.03). Patients in the *EGFR* testing group had greater OS compared to those in the untested group (27.50 vs. 19.73 months; hazard ratio \[HR\] 0.767, 95% CI 0.658--0.894; *P* = 0.007). The one and two‐year OS rates were also higher than those of the untested group (74.10% and 52.60% vs. 64.50% and 43.85%, respectively).

Discussion {#tca12859-sec-0019}
==========

This was a large observational study of the real‐world practice of *EGFR* testing in NSCLC patients from 28 centers covering different levels of cities and hospitals in North China in 2014. We found that 42.54% of stage IIIB/IV NSCLC patients were tested for *EGFR* mutations. This rate was significantly higher than those obtained during 2010--2011 in China,[15](#tca12859-bib-0015){ref-type="ref"}, [16](#tca12859-bib-0016){ref-type="ref"} and is consistent with the professional guidelines for *EGFR* testing released after 2011.[8](#tca12859-bib-0008){ref-type="ref"} These findings indicate that physicians are becoming more aware of the role that *EGFR* mutations play when making decisions over personalized TKI therapy for NSCLC patients. However, given that 90% of patients in this study were selected with advanced adenocarcinoma and were more likely to have undergone *EGFR* status testing,[18](#tca12859-bib-0018){ref-type="ref"}, [19](#tca12859-bib-0019){ref-type="ref"} the true *EGFR* testing rate in North China is still low. The 42.54% test rate in our study sample was lower than the rates found in the CTONG1506 study for 2015--2016 in China (71.4%),[20](#tca12859-bib-0020){ref-type="ref"} as well as in Taiwan (54.3%), and Japan (64.8%) in 2014.[13](#tca12859-bib-0013){ref-type="ref"}, [14](#tca12859-bib-0014){ref-type="ref"}, [16](#tca12859-bib-0016){ref-type="ref"}

The reason why more than half of the patients in this study did not undergo *EGFR* testing is likely multifactorial. In the real‐world setting, multiple clinical and social factors affect *EGFR* testing rates in North China, including patient characteristics, tumor specimen types, *EGFR* detection platforms, and doctors' awareness of *EGFR* testing, as well as the costs associated with *EGFR* testing and TKI therapy.

*EGFR* testing is also more likely to be performed in patients with adenocarcinomas and in non‐smokers. Tumor specimens obtained by lymph node puncture had the highest *EGFR* testing rates (73.51%), followed by those obtained by lung puncture. However, *EGFR* tests are less likely to be conducted in patients treated in Tier‐3 cities. The *EGFR* testing rate in a Tier‐1 city was 69.04% in our study, similar to the 71.4% found in the CTONG1506 study that focused on larger Chinese cities, such as Beijing, Shanghai, and Nanjing.[20](#tca12859-bib-0020){ref-type="ref"} In China, patients covered by rural medical insurance have relatively low incomes. The high costs of *EGFR* testing (46.77%) and TKI therapy (37.66%) discourage a large proportion of patients from undergoing *EGFR* testing, even if recommended by treating doctors. Previous studies have reported that reimbursement of *EGFR* testing costs by medical insurance companies contributes to high *EGFR* testing rates in Japan.[16](#tca12859-bib-0016){ref-type="ref"} Thus, governmental policies that enable reimbursement of *EGFR* testing costs are important to the implementation of *EGFR* testing and TKI therapy regimens for NSCLC patients. The influence of economic burden on *EGFR* testing was further revealed by a study carried out in Canada, which showed that *EGFR* testing rates dropped substantially once related funding was discontinued.[21](#tca12859-bib-0021){ref-type="ref"}

*EGFR* mutation testing can be performed on tumor specimens obtained via many techniques: surgical resection, endoscopy, transthoracic needle biopsy, or lung puncture. In this study, biopsy lymph node punctate samples were the most frequently used specimen for *EGFR* gene testing. Tumor tissue is the gold standard for clinical genetic analyses, but adequate tissue samples are not always available for all patients. Data have shown that cytology samples can be used for *EGFR* mutation testing.[22](#tca12859-bib-0022){ref-type="ref"} Because of the observational nature of our study, the overall agreement between different sample types was not compared. The positive rates of biopsy tumor tissues, cytology specimens, and resected tumor specimens were 48.82%, 45.65%, and 51.97%, respectively. These results are consistent with the findings of a recent study that demonstrated *EGFR* positive rates in histological and cytological samples of 42.5% and 37.5%, respectively.[23](#tca12859-bib-0023){ref-type="ref"} Compared to tissue and cytology samples, blood samples are easily obtained and can also be used for *EGFR* mutation detection,[24](#tca12859-bib-0024){ref-type="ref"} but highly sensitive platforms, such as digital PCR, are required.[25](#tca12859-bib-0025){ref-type="ref"} Although blood samples generate a lower positive rate of *EGFR* testing (20.59%), this method has advantages, especially when adequate tissue samples are not available.[26](#tca12859-bib-0026){ref-type="ref"}

The *EGFR* mutation rate in our study was 46.44% (555/1195), and 86.49% of these were TKI‐sensitive mutations, such as 19 deletions and L858R mutations; these mutations comprised up to 90% of all sensitive mutations, consistent with the results of previous reports.[27](#tca12859-bib-0027){ref-type="ref"} A variety of technology platforms are available to detect *EGFR* mutations, including DNA sequencing, real‐time PCR‐based methods, restriction fragment length polymorphism, mass spectrometry‐based genotyping, peptide nucleic acid clamp, and high‐performance liquid chromatography. DNA sequencing is the initial method used for *EGFR* gene detection, but has low sensitivity; more sensitive methods are required for samples with a low tumor content. Real‐time PCR‐based methods, Sanger DNA sequencing, and Luminex liquid chip were used in our study, and these platforms generated similar positive rates for *EGFR* testing, indicating that physicians can choose appropriate methods in accordance with patient characteristics and techniques available in hospitals.

*EGFR* mutation testing in lung cancer is used to guide patient selection for TKI therapy. In this study, 56.22% of NSCLC patients with *EGFR* mutation were administered TKI therapy. Most international guidelines recommend that TKI therapy should not be prescribed as first‐line therapy for patients without sensitive mutations; however, 5.85% of patients without *EGFR* mutations and 5.27% of *EGFR*‐unknown patients in our sample received TKI therapy. Efforts should be enhanced to further improve the clinical education of the benefits of personalized TKI therapy for doctors and patients.

We also investigated the impact of *EGFR* testing and subsequent first‐line therapy regimens on patient outcomes. Patients in the *EGFR* testing group had better OS compared to those in the untested group (27.50 vs. 19.73 months; *P* = 0.007). This could be associated with TKI therapy because the majority of untested patients did not receive TKI therapy, and *EGFR* testing results are essential in selecting the candidate patients who will benefit most from such therapy. A recent study demonstrated that *EGFR* testing was associated with prolonged OS (HR 0.76; *P* \< 0.0001) because *EGFR*‐mutant patients benefited more from first‐line TKI therapy.[14](#tca12859-bib-0014){ref-type="ref"}

There are several limitations to this study. The major limitation is its retrospective real‐world nature, which might explain why 75.19% of patients were aged \< 65 years. However, several strengths, including the large number of patients, the assessment of *EGFR* testing in clinical settings, and the different platforms and specimens used for *EGFR* testing add to the importance of our findings. Another limitation is that the patients were enrolled in North China; however, the screened patient samples were adequate, and the patient characteristics and *EGFR* mutation rates were similar to previous studies.[15](#tca12859-bib-0015){ref-type="ref"}, [16](#tca12859-bib-0016){ref-type="ref"} We believe the key findings in our study, including *EGFR* testing rates and the clinical and social features affecting *EGFR* testing, can be generalized to China or Asian countries.

In conclusion, the real‐world *EGFR* testing rate is relatively low in North China. Close cooperation between doctors, patients, and government is required to improve the clinical practice of *EGFR* testing in NSCLC patients. These include strengthening education on personalized therapy, increasing doctor and patient awareness of *EGFR* gene detection, and improving social medical insurance coverage in order to further implement *EGFR* testing to benefit NSCLC patients. A variety of *EGFR* testing platforms and techniques are available and generate similar positive rates; therefore doctors are in a position to choose appropriate methods to better support personalized TKI therapy.
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